
ESTA Stock Forecast & Price Target
ESTA Analyst Ratings
Bulls say
Establishment Labs Holdings Inc. demonstrated a significant improvement in its financial performance, with an adjusted EBITDA margin of 2.2%, representing a remarkable increase of 1,960 basis points year-over-year, and exceeding consensus expectations. The company achieved a gross margin of 70.1%, which was 620 basis points higher compared to the previous year, a result attributed to the successful launch of its Motiva implants in the US market. Furthermore, the anticipated increase in cash reserves to $75.5 million by the end of 2026, coupled with a 16% sequential revenue growth in the US, highlights the potential for continued financial strength and resilience in the company's operations.
Bears say
Establishment Labs Holdings Inc. faces a negative outlook due to anticipated revenue growth declining to less than 20%, attributed to weaker-than-expected sales in the U.S. market and slower progression toward profitability. Additionally, the company's international growth has significantly slowed, with projections indicating only 2% growth in 2023, a forecasted 2% decline in 2024, and stagnant growth thereafter. The company also faces several risks, including disappointing U.S. sales of Motiva implants, potential economic downturns affecting international sales, and concerns over complication rates and possible dilutive equity offerings.
This aggregate rating is based on analysts' research of Establishment Labs Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ESTA Analyst Forecast & Price Prediction
Start investing in ESTA
Order type
Buy in
Order amount
Est. shares
0 shares